The partnership will incorporate Singulex’s Single Molecule Counting (SMC™) technology and customized consumables onto Tecan’s Freedom EVO liquid handling platform.

By integrating Singulex’s proprietary ultrasensitive detection technology with Tecan’s existing platform, Singulex expects to be able to commercialize the ultrasensitive immunoassay system for the in vitro diagnostics (IVD) market as early as 2016.

The Sgx Clarity System will be the most sensitive IVD immunoassay system for routine diagnostics. The fully-automated bench-top analyzer is targeted for clinical diagnostics laboratories and is being designed to be marketed by Singulex as an IVD and CE-marked device in the US and global markets.

Singulex president and CEO Guido Baechler noted that the company expects the Sgx Clarity System to be able to detect low-abundance biomarkers and pathogens with significantly greater sensitivity than any existing immunoassay IVD systems.

"By choosing Tecan’s innovative liquid handling platform, we are confident we will offer a fully-automated platform of the highest quality with a reduced time to market," Baechler added.